Ultragenyx Pharmaceutical (NASDAQ:RARE) EVP Sells $46,753.38 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) EVP Karah Herdman Parschauer sold 1,899 shares of the stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total transaction of $46,753.38. Following the completion of the transaction, the executive vice president owned 94,462 shares of the company’s stock, valued at $2,325,654.44. This represents a 1.97% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ultragenyx Pharmaceutical Stock Up 8.3%

Shares of RARE opened at $26.91 on Thursday. The company has a 50-day simple moving average of $24.17 and a 200-day simple moving average of $24.91. The company has a market capitalization of $2.65 billion, a PE ratio of -4.40 and a beta of 0.37. Ultragenyx Pharmaceutical Inc. has a 52-week low of $18.29 and a 52-week high of $42.37.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). The company had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. Ultragenyx Pharmaceutical had a negative net margin of 91.03% and a negative return on equity of 1,024.42%. The business’s revenue for the quarter was down 2.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($1.57) EPS. On average, research analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -4.53 EPS for the current year.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of research analyst reports. Wells Fargo & Company increased their price target on shares of Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a report on Wednesday, May 6th. Cantor Fitzgerald raised their price objective on Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the company an “overweight” rating in a research note on Thursday, May 21st. Wall Street Zen raised Ultragenyx Pharmaceutical from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Barclays dropped their price objective on Ultragenyx Pharmaceutical from $44.00 to $43.00 and set an “overweight” rating for the company in a research note on Wednesday, April 29th. Finally, Wedbush dropped their price objective on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating for the company in a research note on Wednesday, May 6th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $59.56.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the business. Assetmark Inc. increased its holdings in Ultragenyx Pharmaceutical by 1,706.7% during the 3rd quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 1,024 shares in the last quarter. Huntington National Bank increased its position in Ultragenyx Pharmaceutical by 56.2% during the third quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 393 shares in the last quarter. Danske Bank A S purchased a new position in Ultragenyx Pharmaceutical during the third quarter worth $39,000. Parallel Advisors LLC increased its position in Ultragenyx Pharmaceutical by 778.4% during the first quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock worth $34,000 after buying an additional 1,440 shares in the last quarter. Finally, Smartleaf Asset Management LLC increased its position in Ultragenyx Pharmaceutical by 205.4% during the third quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 1,169 shares in the last quarter. 97.67% of the stock is currently owned by hedge funds and other institutional investors.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.